Supplementary Figure S5 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Publication
, Other
Ribas, A; Milhem, MM; Hoimes, CJ; Amin, A; Lao, CD; Conry, RM; Hunt, JP; Daniels, GA; Almubarak, M; Shaheen, M; Medina, T; Barve, M; Abdi, E ...
October 1, 2025
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Ribas, A., Milhem, M. M., Hoimes, C. J., Amin, A., Lao, C. D., Conry, R. M., … Long, G. V. (2025). Supplementary Figure S5 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma. https://doi.org/10.1158/1078-0432.30255662
Ribas, Antoni, Mohammed M. Milhem, Christopher J. Hoimes, Asim Amin, Christopher D. Lao, Robert M. Conry, Jason P. Hunt, et al. “Supplementary Figure S5 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma,” October 1, 2025. https://doi.org/10.1158/1078-0432.30255662.
Ribas A, Milhem MM, Hoimes CJ, Amin A, Lao CD, Conry RM, et al. Supplementary Figure S5 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma. 2025.
Ribas, Antoni, et al. Supplementary Figure S5 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma. 1 Oct. 2025. Crossref, doi:10.1158/1078-0432.30255662.
Ribas A, Milhem MM, Hoimes CJ, Amin A, Lao CD, Conry RM, Hunt JP, Daniels GA, Almubarak M, Shaheen M, Medina T, Barve M, Bishnoi S, Abdi E, Chisamore MJ, Guiducci C, Gomez-Romo J, Candia A, Gamelin E, Coffman RL, Janssen RS, Long GV. Supplementary Figure S5 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma. 2025.